Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
Arvinas, a clinical-stage biotechnology company (Nasdaq: ARVN), has announced that its CFO Sean Cassidy and CSO Ian Taylor will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference. This event is scheduled for November 16 at 10:40 a.m. ET. A live audio webcast of the presentation will be available on Arvinas’ website, with a replay accessible for 30 days post-event.
Arvinas focuses on developing therapies that degrade disease-causing proteins using its proprietary PROTAC® platform, targeting prostate and breast cancer.
- None.
- None.
NEW HAVEN, Conn., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Sean Cassidy, Chief Financial Officer, and Ian Taylor, Ph.D., Chief Scientific Officer, will participate in a fireside chat at the Stifel 2021 Virtual Healthcare Conference on Tuesday, November 16 at 10:40 a.m. ET.
A live audio webcast of the presentation will be available here and on Arvinas’ website at www.arvinas.com. A replay of the webcast will be archived on Arvinas’ website for 30 days following the presentation.
About Arvinas
Arvinas is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC® targeted protein degraders, that are designed to harness the body’s own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. In addition to its robust preclinical pipeline of PROTAC® protein degraders against validated and “undruggable” targets, the company has three clinical-stage programs: ARV-110 and ARV-766 for the treatment of men with metastatic castrate-resistant prostate cancer; and ARV-471 for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. For more information, visit www.arvinas.com.
Investor Contact:
Jeff Boyle
(347) 247-5089
jeff.boyle@arvinas.com
Media Contact:
Kirsten Owens
(203) 584-0307
kirsten.owens@arvinas.com
FAQ
When will the Arvinas fireside chat at the Stifel 2021 Virtual Healthcare Conference take place?
Who will represent Arvinas at the Stifel 2021 Virtual Healthcare Conference?
Where can I access the Arvinas presentation from the Stifel 2021 Virtual Healthcare Conference?
What is the focus of Arvinas' drug development?
What is the stock symbol for Arvinas?
